Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Vaccines|May 28, 2022
Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected ScenarioFrancesco Trevisani, Federico Di Marco, Matteo Floris, et al.
Recenti Progressi in Medicina|December 28, 2020
[Target therapies in translocated ALK lung cancer: treatment management in oncology center of Lazio.]Serena Ricciardi, Fabiana Cecere, Mario Rosario D'Andrea, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2005
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II studyAlessandra Felici, Paolo Carlini, Enzo Maria Ruggeri, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2025
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trialsAndrea Torchia, Arianna Sabatini, Elisabetta Bengala, et al.
Cancer|August 4, 2005
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary treeAlain Gelibter, Paola Malaguti, Serena Di Cosimo, et al.
Cancers|July 2, 2021
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical FeaturesAntonio Passaro, Silvia Novello, Diana Giannarelli, et al.
Antioxidants (Basel, Switzerland)|March 28, 2026
Correlation Between Oxidative Stress and Immune Profiles During Immunotherapy in Metastatic Non-Oncogene-Addicted NSCLC PatientsMariangela Peruzzi, Lucrezia Tuosto, Alain Gelibter, et al.
Cancers|September 17, 2020
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell CarcinomaIlaria Grazia Zizzari, Chiara Napoletano, Alessandra Di Filippo, et al.
Drugs in Context|August 17, 2022
Advanced non-small-cell lung cancer: how to manage <i>EGFR</i> and <i>HER2</i> exon 20 insertion mutation-positive diseaseGiulio Metro, Andrea De Giglio, Biagio Ricciuti, et al.
Expert Opinion on Drug Discovery|October 4, 2013
Advances towards the design and development of personalized non-small-cell lung cancer drug therapySabrina Vari, Sara Pilotto, Marcello Maugeri-Saccà, et al.
Pageof 9